Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what investors should know. Insulet beat...
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
What a brutal six months it’s been for Insulet. The stock has dropped 33.8% and now trades at $204.57, rattling many shareholders. This may have investors wo...
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require strict fasting or water intake restrictions. The approval, which came months ahead of initial analyst expectations, marks a pivotal
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet (NASDAQ:PODD) and its peers. Patient m...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to stron...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
